REMICADE® (infliximab) Overview | Janssen CarePath for Healthcare Professionals
Pivotal Clinical Trials
Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor α-Converting Enzyme in ...
Anti-PCSK9 approvals a boon to Protein A supplier Repligen, analyst
Johnson & Johnson would be just fine without Zytiga, executives insist as patent decision looms | Fierce Pharma